Karin Hohloch

Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group

Stephan Stilgenbauer, Thorsten Zenz, Dirk Winkler et al. · Journal of Clinical Oncology · 2009 · 270 citations · Full text

The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)

Christian Buske, Eva Hoster, Martin Dreyling et al. · Leukemia · 2008 · 155 citations

Lymphoid Neoplasia, Oncology, Immunology +6

Combination Chemotherapy With Gemcitabine Plus Oxaliplatin in Patients With Intensively Pretreated or Refractory Germ Cell Cancer: A Study of the German Testicular Cancer Study Group

Christian Kollmannsberger, J. Beyer, Rüediger Liersch et al. · Journal of Clinical Oncology · 2003 · 155 citations · Full text

Rapid mucosal CD4+ T-cell depletion and enteropathy in simian immunodeficiency virus–infected rhesus macaques

Stephan Kewenig, Thomas Schneider, Karin Hohloch et al. · Gastroenterology · 1999 · 148 citations · Full text

Primary Immunodeficiency, Viral Persistence, Rhesus Macaques +12

Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma

A. Meyer, Andrea Stroux, Kristina Lerch et al. · Annals of Oncology · 2013 · 57 citations · Full text

Adverse Course, Lymphoid Neoplasia, Surgical Oncology +12